

A Meta-Network for Validating Liquid Biopsies Including Patients on New Immune Therapies

12:30 - August 15th, 2017 | Next Generation Dx Summit Session: Companion Diagnostics: Strategy & Partnerships | Grand Hyatt Washington | Washington, DC

Trans-Hit Bio invites you to our presentation at the Next Generation Dx Summit. We will also be on the Exhibit Floor in Booth # 405, please, come see us.

A Meta-Network for Validating Liquid Biopsies Including Patients on New Immune Therapies

Liquid biopsy has the potential to identify patients for a particular therapy and can monitor patients on therapy. This can be particularly useful for patients undergoing immune-oncology therapy. The best results are obtained using unique patient profiles, state-of-the-art processing and specimen transport systems. Despite these efforts, the organization and conduction of large studies are slow and many times impractical. The development of an international consortium is one solution to these issues.

About Trans-Hit Bio

Trans-Hit Biomarkers is a leading human tissue procurement CRO with an extensive collection capability for biospecimens and clinical samples. Through an unrivaled worldwide partnered-network of state-of-the-art biorepositories and clinical sites, Trans-Hit Bio has successfully performed hundreds of clinical sample searches in all therapeutic areas: oncology (including those with specific mutations, liquid biopsies), CNS diseases, infectious diseases, rare diseases ...

The most important tenet of our business is transparency and traceability. In contrast to many other biospecimen providers, we encourage direct interaction between end users and collecting sites (see our recent publication [click here](#)).

Come speak with our Project Directors and discuss your biospecimen needs and challenges.

We look forward to seeing you!

Vanessa